These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 673744)

  • 1. [Type II hyperlipoproteinemia: treatment with colestipol and procetophen].
    Sauvanet JP; Drouin P; Debry G; Mejean L; Lambert D
    Nouv Presse Med; 1978 May; 7(21):1862. PubMed ID: 673744
    [No Abstract]   [Full Text] [Related]  

  • 2. Results of colestipol therapy in Type II hyperlipoproteinemia.
    Lees AM; McCluskey MA; Lees RS
    Atherosclerosis; 1976; 24(1-2):129-40. PubMed ID: 182181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probucol further lowers the serum cholesterol of colestipol-treated patients with hypercholesterolemia.
    Schonfeld G; Witztum J; Basich P
    Artery; 1982; 10(2):99-104. PubMed ID: 7092583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of 6 months, therapy of familial hypercholesterolemia (hyperlipoproteinemia type II) with colestipol].
    Kuŝić M; Gavrilović M; Mihajloviĉ M; Boŝković B
    Srp Arh Celok Lek; 1980 Sep; 108(9):875-81. PubMed ID: 7302695
    [No Abstract]   [Full Text] [Related]  

  • 5. Colestipol in familial type II hyperlipoproteinemia: a three-year trial.
    Harvengt C; Desager JP
    Clin Pharmacol Ther; 1976 Sep; 20(3):310-4. PubMed ID: 182429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long term treatment of familial hypercholesterolemia with Colestipol, a new anionic exchange resin (author's transl)].
    Briani G; Fellin R; Balestrieri P; Baggio G; Baiocchi MR; Crepaldi G
    G Ital Cardiol; 1975; 5(3):390-404. PubMed ID: 1149965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The long-term effects of colestipol hydrochloride on serum and lipoprotein lipids in patients with heterozygous familial hypercholesterolemia (author's transl)].
    Wakasugi T; Sakai T; Watanabe A; Tatami R; Ueda K; Ueda R; Kametani T; Haba T; Koizumi J; Miyamoto S; Mabuchi H; Takeda R; Sakai Y; Yoshimura A; Takegoshi T; Ohta M; Ono S; Ohka T; Takeshita H
    Nihon Ronen Igakkai Zasshi; 1981 Nov; 18(6):432-40. PubMed ID: 7339082
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
    Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerance, and safety of colestipol HCL as a hypocholesterolemic agent in hyperlipidemic patients with studies of its effect on gastrointestinal absorption.
    Faruqui AM; Thurmond MS; Wenger J; Wenger NK
    J Pak Med Assoc; 1981 Nov; 31(11):241-5. PubMed ID: 6802993
    [No Abstract]   [Full Text] [Related]  

  • 10. [Substantiation of increasing doses of statins in clinical practice].
    Susekov AV
    Ter Arkh; 2001; 73(4):76-80. PubMed ID: 11494456
    [No Abstract]   [Full Text] [Related]  

  • 11. Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia.
    Grundy SM; Mok HY
    J Lab Clin Med; 1977 Feb; 89(2):354-66. PubMed ID: 833472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term therapy of hypercholesteremia in diabetics with colestipol].
    Düntsch G
    Fortschr Med; 1981 Jan; 99(3):73-5. PubMed ID: 6781999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.
    Kuo PT; Hayase K; Kostis JB; Moreyra AE
    Circulation; 1979 Feb; 59(2):199-211. PubMed ID: 215338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of the lipid-lowering agent, procetofen, on the makeup of human biliary lipids].
    Grandjean EM; Mordasini R; Paumgartner G
    Schweiz Med Wochenschr; 1979 Apr; 109(16):601-2. PubMed ID: 219470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Procetophen--an alternative in the treatment of hypercholsterinemia?].
    Mordasini R; Grandjean EM; Nobile PC; Paumgartner G; Riva G
    Schweiz Med Wochenschr; 1979 Aug; 109(31):1140-3. PubMed ID: 472702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocholesterolemic activity of colestipol in diabetes.
    Bandisode MS; Boshell BR
    Curr Ther Res Clin Exp; 1975 Aug; 18(2):276-84. PubMed ID: 809240
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of colestipol on plasma lipids in patients affected by type Ii primary hyperlipoproteinaemia (author's transl)].
    Drouin P; Sauvanet JP; Lambert D; Mejean L; Debry G
    Therapie; 1980; 35(4):457-64. PubMed ID: 7466730
    [No Abstract]   [Full Text] [Related]  

  • 18. [Efficacy of procetofen (lipanthyl) in hyperlipidemias (author's transl)].
    Stähelin HB; Seiler W; Pult N
    Schweiz Rundsch Med Prax; 1979 Jan; 68(1):24-8. PubMed ID: 760103
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of hypercholesterolaemia with colestipol: a bile sequestrating agent.
    Nye ER; Jackson D; Hunter JD
    N Z Med J; 1972 Jul; 76(482):12-6. PubMed ID: 4344110
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
    Vecchio TJ; Linden CV; O'Connell MJ; Heilman J
    Arch Intern Med; 1982 Apr; 142(4):721-3. PubMed ID: 7073415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.